Sign In

Login

Password

Forgot Password ? Sign Up

Białko C (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Białko C" in Polish language version.

refsWebsite
Global rank Polish rank
18nih.gov
4th place
7th place
8doi.org
2nd place
6th place
2web.archive.org
1st place
1st place
2aotm.gov.pl
low place
8,056th place
1omim.org
4,380th place
2,468th place
1medscape.com
719th place
1,030th place
1mp.pl
8,738th place
165th place
1fda.gov
447th place
1,118th place
1europa.eu
68th place
31st place
1archive.is
87th place
5th place

aotm.gov.pl

wwwold.aotm.gov.pl

aotm.gov.pl

archive.is

doi.org

  • SL. Pescatore. Clinical management of protein C deficiency.. „Expert Opin Pharmacother”. 2 (3), s. 431-9, Mar 2001. DOI: 10.1517/14656566.2.3.431. PMID: 11336597. 
  • PN. Knoebl. Human protein C concentrates for replacement therapy in congenital and acquired protein C deficiency.. „Drugs Today (Barc)”. 44 (6), s. 429-41, Jun 2008. DOI: 10.1358/dot.2008.44.6.1217993. PMID: 18596997. 
  • M. Levi. Activated protein C in sepsis: a critical review.. „Curr Opin Hematol”. 15 (5), s. 481–6, Sep 2008. DOI: 10.1097/MOH.0b013e328304b3e3. PMID: 18695371. 
  • D. Poole, G. Bertolini, S. Garattini. Errors in the approval process and post-marketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsis.. „Lancet Infect Dis”. 9 (1), s. 67–72, Jan 2009. DOI: 10.1016/S1473-3099(08)70306-2. PMID: 19095197. 
  • PF. Laterre. Clinical trials in severe sepsis with drotrecogin alfa (activated).. „Crit Care”. 11 Suppl 5, s. S5, 2007. DOI: 10.1186/cc6156. PMID: 18269692. 
  • G. Houston, BH. Cuthbertson. Activated protein C for the treatment of severe sepsis.. „Clin Microbiol Infect”. 15 (4), s. 319–24, Apr 2009. DOI: 10.1111/j.1469-0691.2009.02751.x. PMID: 19416303. 
  • JO. Friedrich, NK. Adhikari, MO. Meade. Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?. „Crit Care”. 10 (3), s. 145, 2006. DOI: 10.1186/cc4947. PMID: 16762040. 
  • CA. Gentry, KB. Gross, B. Sud, DA. Drevets. Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions.. „Crit Care Med”. 37 (1), s. 19-25, Jan 2009. DOI: 10.1097/CCM.0b013e318192843b. PMID: 19050637. 

europa.eu

ema.europa.eu

fda.gov

medscape.com

emedicine.medscape.com

mp.pl

nih.gov

ncbi.nlm.nih.gov

  • P. Patracchini, V. Aiello, P. Palazzi, E. Calzolari i inni. Sublocalization of the human protein C gene on chromosome 2q13-q14.. „Hum Genet”. 81 (2), s. 191-2, Jan 1989. PMID: 2912888. 
  • SL. Pescatore. Clinical management of protein C deficiency.. „Expert Opin Pharmacother”. 2 (3), s. 431-9, Mar 2001. DOI: 10.1517/14656566.2.3.431. PMID: 11336597. 
  • CF. Allaart, SR. Poort, FR. Rosendaal, PH. Reitsma i inni. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect.. „Lancet”. 341 (8838), s. 134-8, Jan 1993. PMID: 8093743. 
  • KS. Song, HK. Kim, JW. Song, JR. Choi i inni. A novel silent substitution (C8516T) in exon 9 of the human PROC gene.. „Yonsei Med J”. 42 (3), s. 364-6, Jun 2001. PMID: 11456407. 
  • JL. Brouwer, NJ. Veeger, HC. Kluin-Nelemans, J. van der Meer. The pathogenesis of venous thromboembolism: evidence for multiple interrelated causes.. „Ann Intern Med”. 145 (11), s. 807-15, Dec 2006. PMID: 17146065. 
  • M. Sugiura. Pregnancy and delivery in protein C-deficiency.. „Curr Drug Targets”. 6 (5), s. 577-83, Aug 2005. PMID: 16026278. 
  • PN. Knoebl. Human protein C concentrates for replacement therapy in congenital and acquired protein C deficiency.. „Drugs Today (Barc)”. 44 (6), s. 429-41, Jun 2008. DOI: 10.1358/dot.2008.44.6.1217993. PMID: 18596997. 
  • CL. Gladson, P. Groncy, JH. Griffin. Coumarin necrosis, neonatal purpura fulminans, and protein C deficiency.. „Arch Dermatol”. 123 (12), s. 1701a-1706a, Dec 1987. PMID: 2961308. 
  • F. Mielot, P. Danel, C. Boyer, L. Coulombel i inni. [Acquired deficiencies in antithrombin III and C protein during treatment with L-asparaginase]. „Arch Fr Pediatr”. 44 (3), s. 161-5, Mar 1987. PMID: 2883953. 
  • MC. Guillin, A. Bezeaud. [Protein C, protein S]. „Ann Biol Clin (Paris)”. 45 (2), s. 184-90, 1987. PMID: 3039876. 
  • GR. Bernard, JL. Vincent, PF. Laterre, SP. LaRosa i inni. Efficacy and safety of recombinant human activated protein C for severe sepsis.. „N Engl J Med”. 344 (10), s. 699–709, Mar 2001. PMID: 11236773. 
  • M. Levi. Activated protein C in sepsis: a critical review.. „Curr Opin Hematol”. 15 (5), s. 481–6, Sep 2008. DOI: 10.1097/MOH.0b013e328304b3e3. PMID: 18695371. 
  • D. Poole, G. Bertolini, S. Garattini. Errors in the approval process and post-marketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsis.. „Lancet Infect Dis”. 9 (1), s. 67–72, Jan 2009. DOI: 10.1016/S1473-3099(08)70306-2. PMID: 19095197. 
  • PF. Laterre. Clinical trials in severe sepsis with drotrecogin alfa (activated).. „Crit Care”. 11 Suppl 5, s. S5, 2007. DOI: 10.1186/cc6156. PMID: 18269692. 
  • G. Houston, BH. Cuthbertson. Activated protein C for the treatment of severe sepsis.. „Clin Microbiol Infect”. 15 (4), s. 319–24, Apr 2009. DOI: 10.1111/j.1469-0691.2009.02751.x. PMID: 19416303. 
  • JO. Friedrich, NK. Adhikari, MO. Meade. Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?. „Crit Care”. 10 (3), s. 145, 2006. DOI: 10.1186/cc4947. PMID: 16762040. 
  • CA. Gentry, KB. Gross, B. Sud, DA. Drevets. Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions.. „Crit Care Med”. 37 (1), s. 19-25, Jan 2009. DOI: 10.1097/CCM.0b013e318192843b. PMID: 19050637. 

ghr.nlm.nih.gov

omim.org

web.archive.org